Phospholamban R14del disease: The past, the present and the future

Publication date

2023

Authors

Vafiadaki, Elizabeth
Glijnis, Pieter C.
Doevendans, Pieter A.ISNI 0000000110574516
Kranias, Evangelia G.
Sanoudou, Despina

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Arrhythmogenic cardiomyopathy affects significant number of patients worldwide and is characterized by life-threatening ventricular arrhythmias and sudden cardiac death. Mutations in multiple genes with diverse functions have been reported to date including phospholamban (PLN), a key regulator of sarcoplasmic reticulum (SR) Ca2+ homeostasis and cardiac contractility. The PLN-R14del variant in specific is recognized as the cause in an increasing number of patients worldwide, and extensive investigations have enabled rapid advances towards the delineation of PLN-R14del disease pathogenesis and discovery of an effective treatment. We provide a critical overview of current knowledge on PLN-R14del disease pathophysiology, including clinical, animal model, cellular and biochemical studies, as well as diverse therapeutic approaches that are being pursued. The milestones achieved in <20 years, since the discovery of the PLN R14del mutation (2006), serve as a paradigm of international scientific collaboration and patient involvement towards finding a cure.

Keywords

arrhythmias, cardiomyopathy, phospholamban, precision medicine, R14del mutation, therapy, Cardiology and Cardiovascular Medicine

Citation

Vafiadaki, E, Glijnis, P C, Doevendans, P A, Kranias, E G & Sanoudou, D 2023, 'Phospholamban R14del disease : The past, the present and the future', Frontiers in Cardiovascular Medicine, vol. 10, 1162205. https://doi.org/10.3389/fcvm.2023.1162205